Kineta Property, Plant, and Equipment 2014-2024 | KANT

Kineta property, plant, and equipment from 2014 to 2024. Property, plant, and equipment can be defined as the sum of all net property, plant & Equipment fields. Where companies do not report a break down of plant, property, & equipment, the value is entered in this field alone.
Kineta Annual Property, Plant, and Equipment
(Millions of US $)
2023 $
2022 $0
2021 $0
2020 $1
2019 $1
2018 $1
2017 $0
2016 $1
2015 $1
2014 $1
2013 $1
Kineta Quarterly Property, Plant, and Equipment
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30 $0
2023-06-30 $0
2023-03-31 $0
2022-12-31 $0
2022-09-30 $0
2022-06-30 $0
2022-03-31 $0
2021-12-31 $0
2021-09-30 $0
2021-06-30 $1
2021-03-31 $1
2020-12-31 $1
2020-09-30 $0
2020-06-30 $0
2020-03-31 $0
2019-12-31 $1
2019-09-30 $0
2019-06-30 $1
2019-03-31 $1
2018-12-31 $1
2018-09-30 $1
2018-06-30 $1
2018-03-31 $0
2017-12-31 $0
2017-09-30 $13
2017-06-30 $1
2017-03-31 $1
2016-12-31 $1
2016-09-30 $0
2016-06-30 $0
2016-03-31 $1
2015-12-31 $1
2015-09-30
2015-06-30
2015-03-31
2014-12-31 $3
2013-12-31 $3
Sector Industry Market Cap Revenue
Medical MED-BIOMED/GENE $0.000B $0.005B
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
Stock Name Country Market Cap PE Ratio
Plum Acquisition I (VEEA) United States $0.124B 0.00
Pono Capital Two (SBC) United States $0.036B 0.00
ANEW Medical (KLTO) United States $0.014B 0.00
Tupperware Brands (TUPBQ) United States $0.003B 0.00